Research Progress of Polyethylene Glycol Liposome Doxorubicin in the Treatment of Recurrent Ovarian Cancer

doi:10.12280/gjfckx.20210774

Abstract

Abstract:

Ovarian cancer is insidious and has a high recurrence rate and mortality rate, which seriously threatens women′s life and health. In recent years, the development of pharmaceutical nanotechnology has provided new opportunities for tumor therapy. Polyethylene glycol liposome doxorubicin (PLD) is a small molecular nano particle made by embedding doxorubicin in polyethylene glycol liposomes. It is widely used as a new doxorubicin nano preparation because of its strong targeting, low toxicity to bone marrow and heart and stability of drugs in vivo. It has been proved that PLD alone or in combination can effectively improve the survival time of patients with recurrent ovarian cancer. This paper reviews the research progress of PLD in the treatment of recurrent ovarian cancer with single drug, or combined with trabecotidine, or combined with platinum drugs and maintenance therapy, in order to find a more safe, effective and individualized clinical treatment.

Key words: Doxorubicin, Polyethylene glycols, Liposomes, Ovarian neoplasms, Neoplasm recurrence,local, Platinum

ZHANG Ya-li, KONG Xian-chao. Research Progress of Polyethylene Glycol Liposome Doxorubicin in the Treatment of Recurrent Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 212-216.

References 28

[1]	Piao J, Lee EJ, Lee M. Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis[J]. Gynecol Oncol, 2020, 157(2):542-548. doi: 10.1016/j.ygyno.2020.02.002. doi: 10.1016/j.ygyno.2020.02.002
[2]	Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review[J]. Cancer Biol Med, 2017, 14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084. doi: 10.20892/j.issn.2095-3941.2016.0084
[3]	Buechel M, Herzog TJ, Westin SN, et al. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option[J]. Ann Oncol, 2019, 30(5):721-732. doi: 10.1093/annonc/mdz104. doi: S0923-7534(19)31176-7 pmid: 31987339
[4]	Li XR, Zhu Y, Zhang GN, et al. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials[J]. J Ovarian Res, 2021, 14(1):42. doi: 10.1186/s13048-021-00790-4. doi: 10.1186/s13048-021-00790-4
[5]	Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease[J]. Ann Oncol, 2017, 28(4):727-732. doi: 10.1093/annonc/mdw663. doi: 10.1093/annonc/mdw663 pmid: 27993805
[6]	Colombo N, Sessa C, Bois AD, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease[J]. Ann Oncol, 2019, 30(5):672-705. doi: 10.1093/annonc/mdz062. doi: S0923-7534(19)31162-7 pmid: 31987337
[7]	Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer[J]. Expert Rev Anticancer Ther, 2017, 17(12):1147-1158. doi: 10.1080/14737140.2017.1398088. doi: 10.1080/14737140.2017.1398088
[8]	Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan[J]. J Clin Oncol, 2001, 19(14):3312-3322. doi: 10.1200/JCO.2001.19.14.3312. doi: 10.1200/JCO.2001.19.14.3312 pmid: 11454878
[9]	Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer[J]. Gynecol Oncol, 2004, 95(1):1-8. doi: 10.1016/j.ygyno.2004.07.011. doi: 10.1016/j.ygyno.2004.07.011 pmid: 15385103
[10]	Takahashi Y, Takei Y, Machida S, et al. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine[J]. J Obstet Gynaecol Res, 2021, 47(2):551-559. doi: 10.1111/jog.14558. doi: 10.1111/jog.14558
[11]	Takei Y, Takahashi Y, Machida S, et al. Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens[J]. J Obstet Gynaecol Res, 2017, 43(2):358-364. doi: 10.1111/jog.13203. doi: 10.1111/jog.13203
[12]	Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer[J]. J Clin Oncol, 2010, 28(19):3107-3114. doi: 10.1200/JCO.2009.25.4037. doi: 10.1200/JCO.2009.25.4037
[13]	Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis[J]. Eur J Cancer, 2012, 48(15):2361-2368. doi: 10.1016/j.ejca.2012.04.001. doi: 10.1016/j.ejca.2012.04.001
[14]	Kaye SB, Colombo N, Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval[J]. Ann Oncol, 2011, 22(1):49-58. doi: 10.1093/annonc/mdq353. doi: S0923-7534(19)37794-4 pmid: 20643863
[15]	Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study[J]. J Clin Oncol, 2017, 35(29):3347-3353. doi: 10.1200/JCO.2017.73.4293. doi: 10.1200/JCO.2017.73.4293 pmid: 28825853
[16]	Colombo N, Gadducci A, Sehouli J, et al. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line[J]. Ann Oncol, 2020, 31(Suppl 4):S1161. doi: org/10.1016/j.annonc.2020.08.2260. doi: org/10.1016/j.annonc.2020.08.2260
[17]	Monk BJ, Ghatage P, Parekh T, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study[J]. Ann Oncol, 2015, 26(5):914-920. doi: 10.1093/annonc/mdv071. doi: S0923-7534(19)31513-3 pmid: 25722380
[18]	Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer[J]. Gynecol Oncol, 2020, 156(3):535-544. doi: 10.1016/j.ygyno.2019.12.043. doi: 10.1016/j.ygyno.2019.12.043
[19]	Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505. doi: 10.1056/NEJMoa1810858. doi: 10.1056/NEJMoa1810858
[20]	Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients[J]. Br J Cancer, 2012, 107(4):588-591. doi: 10.1038/bjc.2012.307. doi: 10.1038/bjc.2012.307
[21]	Shi SQ, Jiang FF, Hong T, et al. Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6):2911-2927. doi: 10.26355/eurrev_202003_20655. doi: 10.26355/eurrev_202003_20655
[22]	Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. doi: S1470-2045(20)30142-X pmid: 32305099
[23]	中华医学会妇科肿瘤学分会. 妇科恶性肿瘤聚乙二醇化脂质体多柔比星临床应用专家共识[J]. 现代妇产科进展, 2020, 29(7):481-488. doi: 10.13283/j.cnki.xdfckjz.2020.07.001. doi: 10.13283/j.cnki.xdfckjz.2020.07.001
[24]	Blake EA, Bradley CA, Mostofizadeh S, et al. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study[J]. Arch Gynecol Obstet, 2019, 299(6):1641-1649. doi: 10.1007/s00404-019-05104-0. doi: 10.1007/s00404-019-05104-0 pmid: 30824986
[25]	程晓东, 王芬芬. 复发性卵巢癌的诊治热点[J]. 浙江医学, 2021, 43(15):1593-1599. doi: 10.12056/j.issn.1006-2785.2021.43.15.2021-1746. doi: 10.12056/j.issn.1006-2785.2021.43.15.2021-1746
[26]	Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. doi: 10.1016/S1470-2045(21)00073-5
[27]	Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J]. J Clin Oncol, 2012, 30(4):372-379. doi: 10.1200/JCO.2011.36.9215. doi: 10.1200/JCO.2011.36.9215
[28]	Gonzalez R, Havrilesky LJ, Myers ER, et al. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer[J]. Gynecol Oncol, 2020, 159(2):483-490. doi: 10.1016/j.ygyno.2020.08.003. doi: 10.1016/j.ygyno.2020.08.003 pmid: 32863036